CVRx (CVRX) Stock Forecast & Price Target

CVRx Inc. demonstrated significant growth, achieving a total of 240 active implanting centers by the end of the quarter, an increase of 13 centers sequentially. While total operating expenses rose approximately 8% year-over-year to $25.8 million, this increase was primarily attributed to a 11% rise in selling, general, and administrative expenses, indicating investment in infrastructure to support future growth. The company's strong presence in the U.S. market, combined with its innovative Barostim technology targeting cardiovascular diseases, positions it favorably for continued expansion and revenue generation.

CVRx Inc's recent adjustments to its revenue guidance for FY25 reflect a cautious outlook, with the top end lowered to a range of $55.0 - $57.0 million, indicating a modest growth projection of approximately 7-11% year-over-year. Furthermore, the company's gross margin remained relatively stable at 84% in 2Q25, which does not demonstrate signs of improvement or expansion. Additionally, the downward revision of the 2026 revenue estimate from $74.1 million to $67.6 million signals an anticipated slowdown in revenue growth, particularly in the U.S. market where the majority of its income is generated.